CN116472045B - 使用杂芳基联苯基酰胺衍生物治疗癌症的方法 - Google Patents

使用杂芳基联苯基酰胺衍生物治疗癌症的方法 Download PDF

Info

Publication number
CN116472045B
CN116472045B CN202180059142.3A CN202180059142A CN116472045B CN 116472045 B CN116472045 B CN 116472045B CN 202180059142 A CN202180059142 A CN 202180059142A CN 116472045 B CN116472045 B CN 116472045B
Authority
CN
China
Prior art keywords
cancer
compound
group
formula
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202180059142.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN116472045A (zh
Inventor
李世杰
M·维拉尔塔-科洛玛
曾一斌
张朋烈
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chemocentryx Inc
Original Assignee
Chemocentryx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemocentryx Inc filed Critical Chemocentryx Inc
Publication of CN116472045A publication Critical patent/CN116472045A/zh
Application granted granted Critical
Publication of CN116472045B publication Critical patent/CN116472045B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001111—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202180059142.3A 2020-06-23 2021-06-22 使用杂芳基联苯基酰胺衍生物治疗癌症的方法 Active CN116472045B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063042807P 2020-06-23 2020-06-23
US63/042807 2020-06-23
PCT/US2021/038339 WO2021262627A1 (en) 2020-06-23 2021-06-22 Methods of treating cancer using heteroaryl-biphenyl amide derivatives

Publications (2)

Publication Number Publication Date
CN116472045A CN116472045A (zh) 2023-07-21
CN116472045B true CN116472045B (zh) 2025-05-13

Family

ID=79022859

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180059142.3A Active CN116472045B (zh) 2020-06-23 2021-06-22 使用杂芳基联苯基酰胺衍生物治疗癌症的方法

Country Status (14)

Country Link
US (3) US20210393759A1 (https=)
EP (1) EP4167991A4 (https=)
JP (1) JP7804596B2 (https=)
KR (1) KR20230040993A (https=)
CN (1) CN116472045B (https=)
AU (1) AU2021297216B2 (https=)
BR (1) BR112022026397A2 (https=)
CA (1) CA3187605A1 (https=)
CL (1) CL2022003716A1 (https=)
CO (1) CO2023000703A2 (https=)
IL (1) IL299206A (https=)
MX (1) MX2022016554A (https=)
TW (1) TW202216694A (https=)
WO (1) WO2021262627A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10392405B2 (en) 2017-08-08 2019-08-27 Chemocentryx, Inc. Macrocyclic immunomodulators
US10568874B2 (en) 2018-02-22 2020-02-25 Chemocentryx, Inc. Indane-amines as PD-L1 antagonists
WO2020232256A1 (en) 2019-05-15 2020-11-19 Chemocentryx, Inc. Triaryl compounds for treatment of pd-l1 diseases
BR112021025888A2 (pt) 2019-07-10 2022-04-26 Chemocentryx Inc Indanos como inibidores de pd-l1
JP7736678B2 (ja) 2019-10-16 2025-09-09 ケモセントリックス，インコーポレイティド Ｐｄ－ｌ１疾患の処置のためのヘテロアリール－ビフェニルアミド
ES3064674T3 (en) 2019-10-16 2026-04-28 Chemocentryx Inc Heteroaryl-biphenyl amines for the treatment of pd-l1 diseases

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018119221A1 (en) * 2016-12-22 2018-06-28 Incyte Corporation Pyridine derivatives as immunomodulators
CN111225896A (zh) * 2017-07-28 2020-06-02 凯莫森特里克斯股份有限公司 免疫调节剂化合物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102448938A (zh) * 2009-03-27 2012-05-09 阿迪生物科学公司 作为mek抑制剂的二氢吡啶磺酰胺和二氢吡啶硫酰胺
SG11201402004YA (en) * 2011-11-14 2014-05-29 Cephalon Inc Uracil derivatives as axl and c-met kinase inhibitors
EP2788000B1 (en) * 2011-12-06 2018-05-30 Merck Sharp & Dohme Corp. Pyrrolopyrimidines as janus kinase inhibitors
JP7101678B2 (ja) * 2016-12-22 2022-07-15 インサイト・コーポレイション 免疫調節剤としての複素環式化合物
CN106674136B (zh) * 2016-12-23 2019-07-02 中国医科大学 嘧啶类抗肿瘤化合物及其制备方法
CA3092362A1 (en) * 2017-10-19 2019-04-25 Tempest Therapeutics, Inc. Picolinamide compounds
CR20200347A (es) * 2018-02-13 2020-09-23 Gilead Sciences Inc Inhibidores pd-1/pd-l1
US10568874B2 (en) * 2018-02-22 2020-02-25 Chemocentryx, Inc. Indane-amines as PD-L1 antagonists
WO2020232256A1 (en) 2019-05-15 2020-11-19 Chemocentryx, Inc. Triaryl compounds for treatment of pd-l1 diseases
JP7736678B2 (ja) * 2019-10-16 2025-09-09 ケモセントリックス，インコーポレイティド Ｐｄ－ｌ１疾患の処置のためのヘテロアリール－ビフェニルアミド

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018119221A1 (en) * 2016-12-22 2018-06-28 Incyte Corporation Pyridine derivatives as immunomodulators
CN111225896A (zh) * 2017-07-28 2020-06-02 凯莫森特里克斯股份有限公司 免疫调节剂化合物

Also Published As

Publication number Publication date
TW202216694A (zh) 2022-05-01
US20240115682A1 (en) 2024-04-11
AU2021297216B2 (en) 2025-10-16
BR112022026397A2 (pt) 2023-03-14
AU2021297216A1 (en) 2023-02-02
IL299206A (en) 2023-02-01
CO2023000703A2 (es) 2023-01-26
US20210393759A1 (en) 2021-12-23
CN116472045A (zh) 2023-07-21
WO2021262627A1 (en) 2021-12-30
CA3187605A1 (en) 2021-12-30
US20250090646A1 (en) 2025-03-20
MX2022016554A (es) 2023-04-10
EP4167991A4 (en) 2024-07-24
JP7804596B2 (ja) 2026-01-22
KR20230040993A (ko) 2023-03-23
CL2022003716A1 (es) 2023-06-30
EP4167991A1 (en) 2023-04-26
JP2023531970A (ja) 2023-07-26

Similar Documents

Publication Publication Date Title
CN116472045B (zh) 使用杂芳基联苯基酰胺衍生物治疗癌症的方法
CN114340633B (zh) 用于治疗pd-l1疾病的三芳基化合物
ES2951809T3 (es) Derivados de quinazolina-pirazol para el tratamiento de trastornos relacionados con el cáncer
ES2816060T3 (es) Aza-aril 1H-pirazol-1-il-bencenosulfonamidas como antagonistas de CCR(9)
RU2405783C2 (ru) Гетеробициклические ингибиторы вируса гепатита с (hcv)
KR20220119458A (ko) T 세포 활성화제로서 유용한 치환된 헤테로아릴 화합물
CN115697980A (zh) 作为dgkzeta抑制剂用于免疫活化的取代的氨基噻唑
TW202136239A (zh) 用於治療與ｓｔｉｎｇ活性相關之病狀的化合物及組合物
CA3214244A1 (en) Pyridinyl substituted oxoisoindoline compounds
US20250129061A1 (en) Substituted phenyl oxazolone compounds
WO2025064197A1 (en) Substituted azetidinyl oxoisoindolinyl piperidine-2,6-dione compounds
EP4568957A1 (en) Substituted phenyl oxooxazolyl piperidine dione compounds
EP4366832A1 (en) Treatment for cryopyrin associated periodic syndromes (caps)
EA049712B1 (ru) Способы лечения рака с использованием производных гетероарилбифениламида
WO2025226767A1 (en) Substituted 3-(5-(6-aminopyridin-2-yl)-4-fluoro-1-oxoisoindolin-2-yl)piperidine-2,6-dione compounds for use in the treatment of cancer
JP2024502648A (ja) 架橋ヘテロシクリル置換ピリミジン化合物、その調製方法及び医学的使用
EA053150B1 (ru) Замещенные соединения фенилоксазолона

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant